^
    Back
    Association details:
    Biomarker:LDH elevation
    Cancer:Renal Cell Carcinoma
    Drug:Inlyta (axitinib) (VEGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Kidney Cancer
    Title:

    Axitinib beyond first-line therapy of Metastatic Renal Cell Carcinoma: Real World Data from the STAR-TOR registry

    Published date:
    05/22/2023
    Excerpt:
    To evaluate the effectiveness and safety profile of the tyrosine kinase inhibitor Axitinib for patients with advanced or metastatic renal cell carcinoma (a/mRCC) in a real-world setting….Patients with lactate dehydrogenase (LDH) levels >  300U/l had a nominally significantly shorter OS than patients with LDH≤300U/l (8.2 vs. 19.0 months, p = 0.008).
    DOI:
    10.3233/KCA-220011